Shares of NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) have been given a consensus recommendation of “Hold” by the eight ratings firms that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $6.60.

NBY has been the subject of a number of recent research reports. ValuEngine downgraded NovaBay Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, November 10th. Zacks Investment Research downgraded NovaBay Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, September 28th. dropped their price target on NovaBay Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, November 15th. Roth Capital set a $5.00 price target on NovaBay Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 23rd. Finally, HC Wainwright set a $6.00 price target on NovaBay Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, November 15th.

NovaBay Pharmaceuticals (NYSEAMERICAN NBY) opened at $3.40 on Friday. NovaBay Pharmaceuticals has a 52 week low of $2.25 and a 52 week high of $5.00.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last announced its quarterly earnings data on Tuesday, November 14th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.09). The company had revenue of $4.09 million for the quarter, compared to the consensus estimate of $4.69 million. NovaBay Pharmaceuticals had a negative net margin of 42.16% and a negative return on equity of 184.30%.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/22/novabay-pharmaceuticals-inc-nby-given-average-rating-of-hold-by-brokerages.html.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.

Analyst Recommendations for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.